CBUS
Biotechnology · Healthcare
Board Member, Chairman
2023-05-31–present
Board Member
Cibus, Inc. (CBUS)Chairman
Cibus, Inc. (CBUS)Equibles does not estimate personal net worth.
Get an email with a short summary when Cibus, Inc. publishes a filing, an earnings call transcript or a press release.
Get CBUS alertsRory Riggs is recorded as Board Member and Chairman at Cibus, Inc. (CBUS) since May 31, 2023. Cibus, Inc. reported in an 8-K filed February 28, 2025 that Rory Riggs resigned as Chief Executive Officer, effective February 24, 2025. Cibus, Inc. reported in an 8-K filed June 1, 2023 that Rory Riggs was appointed Chief Executive Officer and principal executive officer, effective May 31, 2023. Cibus, Inc. reported in an 8-K filed June 1, 2023 that Rory Riggs was appointed Chair of the Board, effective May 31, 2023. Equibles holds 4 filed executive changes naming Rory Riggs; each is listed under recent activity with its source filing. The proxy statement of Cibus, Inc. reports total compensation of $302,361 for Rory Riggs in fiscal 2025, including a base salary of $161,542. Disclosed compensation is on record for 3 fiscal years. Rory Riggs has spoken on 6 earnings calls across 1 company, most recently for Cibus, Inc. on November 7, 2024. Cibus, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Cibus, Inc. includes Craig Wichner (CEO and Board Member), Michael Carr (CEO), Peter Beetham (CEO, COO and Board Member) and 7 others.
“On February 24, 2025, Rory Riggs resigned as the Chief Executive Officer of Cibus, Inc. (the "Company").”
“Immediately following the First Blocker Merger Effective Time, the Board appointed Rory Riggs as the Company's Chief Executive Officer and principal executive officer, Peter Beetham, Ph.D. as President and Chief Operating Officer, Greg Gocal, Ph.D. as Chief Scientific Officer and Executive Vice President and Wade King, M.D. as the Company's Chief Financial Officer, principal financial officer and principal accounting officer, each to serve at the discretion of the Board.”
“Before I begin, I'd like to recognize Carlo's participation on today's call as our Chief Financial Officer. Carlo has stepped in for Wade King following Wade's leave of absence.”
“I would like to begin this call with a high-level update on our business activities in this quarter and in this year. Following my remarks, Peter will walk you through our recent developments in more detail.”
“I'll begin today's call with a high-level update of our business this quarter. Then Peter will walk you through our recent Q1 commercial progress and discuss how we're doing on our expected 2024 milestones.”
“Today, I will provide a high-level overview of our progress in 2023 and how the events of the last year differentiated us in this emerging industry. Peter will walk you through our recent commercial progress with our products and some milestones we expect to achieve this year.”
“I'll begin by highlighting several of our recent business and commercial updates. Then Peter and I will walk you through where we are and where we are headed. Lastly, Wade will finish with a brief discussion of the financials.”
2023-05-31–present
2023-05-31–present
2023-05-31–2025-02-24
2023-05-31–2025-02-24
Start not stated–2025-02-24
CBUS
Biotechnology · Healthcare
Board Member, Chairman
2023-05-31–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cibus, Inc. (CBUS) | Former Chief Executive Officer | $161,542 | $302,361 |
| 2024 | Cibus, Inc. (CBUS) | Former Chief Executive Officer | $500,011 | $500,011 |
| 2023 | Cibus, Inc. (CBUS) | Former Chief Executive Officer | $292,314 | $292,314 |